NCT04576156Phase 3Active not recruiting

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Study sponsor: Geron Corporation

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-06-30Estimated
Enrollment · participants327Actual
Source updated2026-07-08Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 320 participants (planned). After: 327 participants (actual).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview